These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 930745)

  • 1. The Parkinsonian syndrome and its dopamine correlates.
    Hoehn MM; Crowley TJ; Rutledge CO
    Adv Exp Med Biol; 1977; 90():243-54. PubMed ID: 930745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine excretion and vulnerability to drug-induced Parkinsonism. Schizophrenic patients.
    Crowley TJ; Hoehn MM; Rutledge CO; Stallings MA; Heaton RK; Sundell S; Stilson D
    Arch Gen Psychiatry; 1978 Jan; 35(1):97-104. PubMed ID: 619844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conjugation of L-DOPA and its metabolites after oral and intravenous administration to Parkinsonian patients.
    Bronaugh RL; MacMurtry RJ; Hoehn MM; Rutledge CO
    Biochem Pharmacol; 1975 Jul; 24(13-14):1317-20. PubMed ID: 1096899
    [No Abstract]   [Full Text] [Related]  

  • 4. [Catecholamine metabolism in different forms of Parkinson's disease].
    Selikhova MV; Kogan BM; Serkin GV; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):37-40. PubMed ID: 12378880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced urinary excretion of dopamine and metabolites in chronic renal parenchymal disease.
    Pestana M; Jardim H; Serrão P; Soares-da-Silva P; Guerra L
    Kidney Blood Press Res; 1998; 21(1):59-65. PubMed ID: 9661138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary noradrenaline and serotonin metabolites in drug-free Parkinson patients and the effect of L-dopa treatment.
    Markianos M; Hadjikonstantinou M; Bistolaki E
    Acta Neurol Scand; 1982 Aug; 66(2):267-75. PubMed ID: 6182730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine correlates of neurological and psychological status in untreated Parkinsonism.
    Hoehn MM; Crowley TJ; Rutledge CO
    J Neurol Neurosurg Psychiatry; 1976 Oct; 39(10):941-51. PubMed ID: 1003240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased dopamine and homovanillic acid excretion in a case with chlorpromazine-induced Parkinsonism.
    Messiha FS; Turek I
    Res Commun Chem Pathol Pharmacol; 1973 Jul; 6(1):329-30. PubMed ID: 4734007
    [No Abstract]   [Full Text] [Related]  

  • 9. Urinary homovanillic acid and c-AMP in drug-free Parkinson patients: effect of L-dopa treatment.
    Markianos M; Hadjikonstantinou M
    Eur Neurol; 1981; 20(2):118-24. PubMed ID: 6260505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proceedings: Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and parkinsonian subjects.
    Jones DG; Lenman JA; Robertson MA; Turnbull MJ
    Br J Pharmacol; 1972 Feb; 44(2):386P-387P. PubMed ID: 4668639
    [No Abstract]   [Full Text] [Related]  

  • 11. Low urinary dopamine and prediction of phenothiazine-induced Parkinsonism: a preliminary report.
    Crowley TJ; Rutledge CO; Hoehn MM; Stallings MA; Sundell S
    Am J Psychiatry; 1976 Jun; 133(6):703-6. PubMed ID: 1275103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulphate conjugation and L-dopa treatment of Parkinsonian patients.
    Rutledge CO; Hoehn MM
    Nature; 1973 Aug; 244(5416):447-50. PubMed ID: 4582501
    [No Abstract]   [Full Text] [Related]  

  • 13. Renal dopaminergic system in nephrotic syndrome and after remission.
    Pestana M; Jardim H; Afonso C; Serrão P; Santos N; Guerra L; Soares-da-Silva P
    Nephrol Dial Transplant; 1998 Oct; 13(10):2559-62. PubMed ID: 9794559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of endogenous dopamine metabolism in Gilles de la Tourette's disease.
    Messiha FS; Knopp W
    Dis Nerv Syst; 1976 Aug; 37(8):470-3. PubMed ID: 1066216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease: the effect of L-dopa therapy on urinary free catecholamines and metabolites.
    Davidson DF; Grosset K; Grosset D
    Ann Clin Biochem; 2007 Jul; 44(Pt 4):364-8. PubMed ID: 17594783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Disturbances of catecholamine metabolism (with special reference to dopamine) in the Parkinsonian syndrome].
    Tissot R
    Presse Med (1893); 1969 Apr; 77(17):617-8. PubMed ID: 5785080
    [No Abstract]   [Full Text] [Related]  

  • 17. Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease.
    Streifler M; Vardi Y; Kesten M; Oberman Z; Herzberg M
    Isr J Med Sci; 1972 May; 81(5):597-601. PubMed ID: 5042950
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term effects of unilateral 6-hydroxydopamine destruction of the dopaminergic nigrostriatal pathway on the urinary excretion of catecholamines (dopamine, norepinephrine, epinephrine) and their metabolites in the rat.
    Peyrin L; Cottet-Emard JM; Javoy F; Agid Y; Herbet A; Glowinski J
    Brain Res; 1978 Mar; 143(3):567-72. PubMed ID: 274167
    [No Abstract]   [Full Text] [Related]  

  • 19. Dopamine deficiency in the cerebral cortex in Parkinson disease.
    Scatton B; Rouquier L; Javoy-Agid F; Agid Y
    Neurology; 1982 Sep; 32(9):1039-40. PubMed ID: 7202156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal correlates of the inadequate natriuretic response to salt loading in idiopathic edema.
    Kuchel O; Buu NT; Racz K; Gutkowska J
    Clin Invest Med; 1987 Mar; 10(2):71-7. PubMed ID: 3555912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.